Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition

Basic Research in Cardiology

Volumn 109, Issue 4, 2014, Pages

  Fraccarollo, Daniela ^a   Galuppo, Paolo ^a   Motschenbacher, Stephanie ^b   Ruetten, Hartmut ^c   Schäfer, Andreas ^a   Bauersachs, Johann ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

Heart failure; Myocardial infarction; Remodeling; Soluble guanylyl cyclase

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ATACIGUAT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANYLATE CYCLASE; NITRIC OXIDE; RAMIPRIL; SUPEROXIDE; TRANSFORMING GROWTH FACTOR BETA1; 5-CHLORO-2-(5-CHLOROTHIOPHENE-2-SULFONYLAMINO)-N-(4-(MORPHOLINE-4-SULFONYL)PHENYL)BENZAMIDE; ANTHRANILIC ACID DERIVATIVE; CARDIOTONIC AGENT; CELL RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME ACTIVATOR; NOS3 PROTEIN, RAT; SOLUBLE GUANYLYL CYCLASE; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL INTERACTION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; FIBROBLAST; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; HUMAN CELL; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; TREATMENT OUTCOME; ANIMAL; CELL COMMUNICATION; CELL CULTURE; COMPARATIVE STUDY; COMPLICATION; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; ENZYMOLOGY; EXTRACELLULAR MATRIX; FIBROSIS; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MITOCHONDRION; HEMODYNAMICS; METABOLISM; MOUSE; MYOFIBROBLAST; PATHOLOGY; PATHOPHYSIOLOGY; TIME; WISTAR RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOTONIC AGENTS; CELL COMMUNICATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; ENZYME ACTIVATION; ENZYME ACTIVATORS; EXTRACELLULAR MATRIX; FIBROSIS; GUANYLATE CYCLASE; HEART FAILURE; HEMODYNAMICS; HUMANS; MALE; MICE; MITOCHONDRIA, HEART; MYOCARDIAL CONTRACTION; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; MYOFIBROBLASTS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; ORTHO-AMINOBENZOATES; OXIDATIVE STRESS; RAMIPRIL; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SULFONAMIDES; SUPEROXIDES; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84901872629     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-014-0421-1     Document Type: Article

References (48)

1. Bayeva M, Gheorghiade M, Ardehali H (2013) Mitochondria as a therapeutic target in heart failure. J Am Coll Cardiol 61:599-610. doi:10.1016/j.jacc.2012. 08.1021
2. Bice JS, Keim Y, Stasch JP, Baxter GF (2014) NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size. Cardiovasc Res 101:220-228. doi:10.1093/cvr/cvt257
3. Bonderman D, Ghio S, Felix SB, Ghofrani HA, Michelakis E, Mitrovic V, Oudiz RJ, Boateng F, Scalise AV, Roessig L, Semigran MJ (2013) Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 128:502-511. doi:10.1161/ CIRCULATIONAHA.113.001458
4. Burchfield JS, Xie M, Hill JA (2013) Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation 128:388-400. doi:10.1161/CIRCULATIONAHA. 113.001878
5. D'Souza KM, Malhotra R, Philip JL, Staron ML, Theccanat T, Jeevanandam V, Akhter SA (2011) G protein-coupled receptor kinase-2 is a novel regulator of collagen synthesis in adult human cardiac fibroblasts. J Biol Chem 286:15507-15516. doi:10.1074/jbc.M111.218263
6. Erdmann E, Semigran MJ, Nieminen MS, Gheorghiade M, Agrawal R, Mitrovic V, Mebazaa A (2013) Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. Eur Heart J 34:57-67. doi:10.1093/eurheartj/ehs196
7. Erdmann J, Stark K, Esslinger UB, Rumpf PM, Koesling D, de Wit C, Kaiser FJ, Braunholz D, Medack A, Fischer M, Zimmermann ME, Tennstedt S, Graf E, Eck S, Aherrahrou Z, Nahrstaedt J, Willenborg C, Bruse P, Braenne I, Nothen MM, Hofmann P, Braund PS, Mergia E, Reinhard W, Burgdorf C, Schreiber S, Balmforth AJ, Hall AS, Bertram L, Steinhagen-Thiessen E, Li SC, Marz W, Reilly M, Kathiresan S, McPherson R, Walter U, Cardiogram, Ott J, Samani NJ, Strom TM, Meitinger T, Hengstenberg C, Schunkert H (2013) Dysfunctional nitric oxide signalling increases risk of myocardial infarction. Nature 504:432-436. doi:10.1038/nature12722
8. Fraccarollo D, Berger S, Galuppo P, Kneitz S, Hein L, Schutz G, Frantz S, Ertl G, Bauersachs J (2011) Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 123:400-408. doi:10.1161/CIRCULATIONAHA.110.983023
9. Fraccarollo D, Widder JD, Galuppo P, Thum T, Tsikas D, Hoffmann M, Ruetten H, Ertl G, Bauersachs J (2008) Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 118:818-827. doi:10.1161/CIRCULATIONAHA.107.717702
10. Frantz S, Klaiber M, Baba HA, Oberwinkler H, Volker K, Gabetaner B, Bayer B, Abebetaer M, Schuh K, Feil R, Hofmann F, Kuhn M (2013) Stress-dependent dilated cardiomyopathy in mice with cardiomyocyte-restricted inactivation of cyclic GMP-dependent protein kinase I. Eur Heart J 34:1233-1244. doi:10.1093/eurheartj/ehr445
11. Fujiu K, Nagai R (2013) Contributions of cardiomyocyte-cardiac fibroblast-immune cell interactions in heart failure development. Basic Res Cardiol 108:357. doi:10.1007/s00395-013-0357-x
12. Gheorghiade M, Marti CN, Sabbah HN, Roessig L, Greene SJ, Bohm M, Burnett JC, Campia U, Cleland JG, Collins SP, Fonarow GC, Levy PD, Metra M, Pitt B, Ponikowski P, Sato N, Voors AA, Stasch JP, Butler J (2013) Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail Rev 18:123-134. doi:10.1007/s10741-012-9323-1
13. Ghofrani HA, D'Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, Mayer E, Simonneau G, Wilkins MR, Fritsch A, Neuser D, Weimann G, Wang C (2013) Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369:319-329. doi:10.1056/NEJMoa1209657
14. Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ (2013) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369:330-340. doi:10.1056/NEJMoa1209655
15. Gorbe A, Giricz Z, Szunyog A, Csont T, Burley DS, Baxter GF, Ferdinandy P (2010) Role of cGMP-PKG signaling in the protection of neonatal rat cardiac myocytes subjected to simulated ischemia/reoxygenation. Basic Res Cardiol 105:643-650. doi:10.1007/s00395-010-0097-0
16. Hafstad AD, Nabeebaccus AA, Shah AM (2013) Novel aspects of ROS signalling in heart failure. Basic Res Cardiol 108:359. doi:10.1007/s00395-013- 0359-8
17. Heusch G, Libby P, Gersh B, Yellon D, Bohm M, Lopaschuk G, Opie L (2014) Cardiovascular remodelling in coronary artery disease and heart failure. Lancet. doi:10.1016/S0140-6736(14)60107-0 (Epub ahead of print)
18. Heusch P, Aker S, Boengler K, Deindl E, van de Sand A, Klein K, Rassaf T, Konietzka I, Sewell A, Menazza S, Canton M, Heusch G, Di Lisa F, Schulz R (2010) Increased inducible nitric oxide synthase and arginase II expression in heart failure: no net nitrite/nitrate production and protein S-nitrosylation. Am J Physiol Heart Circ Physiol 299:H446-H453. doi:10.1152/ajpheart.01034.2009
19. Holley AK, Bakthavatchalu V, Velez-Roman JM, St Clair DK (2011) Manganese superoxide dismutase: guardian of the powerhouse. Int J Mol Sci 12:7114-7162. doi:10.3390/ijms12107114
20. Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E (2002) Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:985-992 (Pubitemid 36121052)
21. Kakkar R, Lee RT (2010) Intramyocardial fibroblast myocyte communication. Circ Res 106:47-57. doi:10.1161/CIRCRESAHA.109.207456
22. Korkmaz S, Radovits T, Barnucz E, Hirschberg K, Neugebauer P, Loganathan S, Veres G, Pali S, Seidel B, Zollner S, Karck M, Szabo G (2009) Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury. Circulation 120:677-686. doi:10.1161/CIRCULATIONAHA.109.870774
23. Liu Y, Dillon AR, Tillson M, Makarewich C, Nguyen V, Dell'Italia L, Sabri AK, Rizzo V, Tsai EJ (2013) Volume overload induces differential spatiotemporal regulation of myocardial soluble guanylyl cyclase in eccentric hypertrophy and heart failure. J Mol Cell Cardiol 60:72-83. doi:10.1016/j.yjmcc.2013.03.019
24. Masuyama H, Tsuruda T, Kato J, Imamura T, Asada Y, Stasch JP, Kitamura K, Eto T (2006) Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats. Hypertension 48:972-978. doi:10.1161/01.HYP.0000241087.12492.47 (Pubitemid 44611012)
25. Masuyama H, Tsuruda T, Sekita Y, Hatakeyama K, Imamura T, Kato J, Asada Y, Stasch JP, Kitamura K (2009) Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. Hypertens Res 32:597-603. doi:10.1038/hr.2009.64
26. Methner C, Lukowski R, Grube K, Loga F, Smith RA, Murphy MP, Hofmann F, Krieg T (2013) Protection through postconditioning or a mitochondria-targeted S-nitrosothiol is unaffected by cardiomyocyte-selective ablation of protein kinase G. Basic Res Cardiol 108:337. doi:10.1007/s00395-013-0337-1
27. Mitsuishi M, Miyashita K, Itoh H (2008) cGMP rescues mitochondrial dysfunction induced by glucose and insulin in myocytes. Biochem Biophys Res Commun 367:840-845. doi:10.1016/j.bbrc.2008.01.017
28. Oberwittler H, Hirschfeld-Warneken A, Wesch R, Willerich H, Teichert L, Lehr KH, Ding R, Haefeli WE, Mikus G (2007) Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766. J Clin Pharmacol 47:70-77. doi:10.1177/0091270006294540 (Pubitemid 44974000)
29. Oelze M, Mollnau H, Hoffmann N, Warnholtz A, Bodenschatz M, Smolenski A, Walter U, Skatchkov M, Meinertz T, Munzel T (2000) Vasodilator-stimulated phosphoprotein serine 239 phosphorylation as a sensitive monitor of defective nitric oxide/cGMP signaling and endothelial dysfunction. Circ Res 87:999-1005. doi:10.1161/01.RES.87.11.999
30. Pacher P, Beckman JS, Liaudet L (2007) Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87:315-424. doi:10.1152/physrev.00029.2006 (Pubitemid 46217686)
31. Perrino C, Schiattarella GG, Sannino A, Pironti G, Petretta MP, Cannavo A, Gargiulo G, Ilardi F, Magliulo F, Franzone A, Carotenuto G, Serino F, Altobelli GG, Cimini V, Cuocolo A, Lombardi A, Goglia F, Indolfi C, Trimarco B, Esposito G (2013) Genetic deletion of uncoupling protein 3 exaggerates apoptotic cell death in the ischemic heart leading to heart failure. J Am Heart Assoc 2:e000086. doi:10.1161/JAHA.113.000086
32. Razeghi P, Young ME, Ying J, Depre C, Uray IP, Kolesar J, Shipley GL, Moravec CS, Davies PJ, Frazier OH, Taegtmeyer H (2002) Downregulation of metabolic gene expression in failing human heart before and after mechanical unloading. Cardiology 97:203-209
33. Sabbah HN, Gupta RC, Kohli S, Wang M, Rastogi S, Zhang K, Zimmermann K, Diedrichs N, Albrecht-Kupper BE (2013) Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure. Circ Heart Fail 6:563-571. doi:10.1161/ CIRCHEARTFAILURE.112.000208
34. Salloum FN, Das A, Samidurai A, Hoke NN, Chau VQ, Ockaili RA, Stasch JP, Kukreja RC (2012) Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide. Am J Physiol Heart Circ Physiol 302:H1347-H1354. doi:10.1152/ajpheart.00544.2011
35. Schafer A, Flierl U, Kobsar A, Eigenthaler M, Ertl G, Bauersachs J (2006) Soluble guanylyl cyclase activation with HMR1766 attenuates platelet activation in diabetic rats. Arterioscler Thromb Vasc Biol 26:2813-2818. doi:10.1161/01.ATV.0000249407.92147.12
36. Schafer A, Fraccarollo D, Werner L, Bauersachs J (2010) Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure. Pharmacol Res 62:432-438. doi:10.1016/j.phrs.2010.06.008
37. Schafer A, Galuppo P, Fraccarollo D, Vogt C, Widder JD, Pfrang J, Tas P, Barbosa-Sicard E, Ruetten H, Ertl G, Fleming I, Bauersachs J (2010) Increased cytochrome P4502E1 expression and altered hydroxyeicosatetraenoic acid formation mediate diabetic vascular dysfunction: rescue by guanylyl-cyclase activation. Diabetes 59:2001-2009. doi:10.2337/db09-1668
38. Schindler U, Strobel H, Schonafinger K, Linz W, Lohn M, Martorana PA, Rutten H, Schindler PW, Busch AE, Sohn M, Topfer A, Pistorius A, Jannek C, Mulsch A (2006) Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase. Mol Pharmacol 69:1260-1268. doi:10.1124/mol.105.018747
39. Slinker BK (1998) The statistics of synergism. J Mol Cell Cardiol 30:723-731. doi:10.1006/jmcc.1998.0655
40. Stasch JP, Pacher P, Evgenov OV (2011) Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123:2263-2273. doi:10.1161/CIRCULATIONAHA.110.981738
41. Toime LJ, BrandMD(2010) Uncoupling protein-3 lowers reactive oxygen species production in isolated mitochondria. Free Radic Biol Med 49:606-611. doi:10.1016/j.freeradbiomed.2010.05.010
42. Tsai EJ, Kass DA (2009) Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. Pharmacol Ther 122:216-238. doi:10.1016/j.pharmthera.2009.02.009
43. Tsai EJ, Liu Y, Koitabashi N, Bedja D, Danner T, Jasmin JF, Lisanti MP, Friebe A, Takimoto E, Kass DA (2012) Pressure-overload- induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation. Circ Res 110:295-303. doi:10.1161/CIRCRESAHA.111.259242
44. Tsutsui H, Kinugawa S, Matsushima S (2009) Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc Res 81:449-456. doi:10.1093/cvr/cvn280
45. Tullio F, Angotti C, Perrelli MG, Penna C, Pagliaro P (2013) Redox balance and cardioprotection. Basic Res Cardiol 108:392. doi:10.1007/s00395-013- 0392-7
46. Wang X, Gong J, Liu X, Zhan R, Kong R, Zhao Y, Wan D, Leng X, Chen M, Qian L (2010) Expression of uncoupling protein 3 in mitochondria protects against stress-induced myocardial injury: a proteomic study. Cell Stress Chaperones 15:771-779. doi:10.1007/s12192-010-0185-y
47. Westermann D, Becher PM, Lindner D, Savvatis K, Xia Y, Frohlich M, Hoffmann S, Schultheiss HP, Tschope C (2012) Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo. Basic Res Cardiol 107:308. doi:10.1007/s00395-012-0308-y
48. Xie M, Burchfield JS, Hill JA (2013) Pathological ventricular remodeling: therapies: part 2 of 2. Circulation 128:1021-1030. doi:10.1161/CIRCULATIONAHA. 113.001879